TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 18789007
Drug: Acridilol therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acridilol therapy
Study: 15991507
Drug: Bupivacaine 0.125%
Normalized name: BUPIVACAINE 0.125%/NS INJ 250ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine 0.125% with 1:200000 epinephrine, 20 mL administered through a subphrenic catheter before incision closure and at 4-hourly intervals for the first postoperative 20 hours.
Study: 15991507
Drug: Saline with
Normalized name: CVS Saline with Aloe Nasal Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline with 1:200000 epinephrine, 20 mL administered through a subphrenic catheter before incision closure and at 4-hourly intervals for the first postoperative 20 hours.
Study: 12182251
Drug: Losartan 100
Normalized name: LOSARTAN 100MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 100 mg/hydrochlorothiazide 25 mg (L100/25)
Study: 12182251
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg/hydrochlorothiazide 12.5 mg (L50/12.5)
Study: 10482058
Drug: Bordetella pertussis
Normalized name: Bordetella pertussis
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bordetella pertussis (single agent)
Study: 10482058
Drug: Bordetella parapertussis
Normalized name: Bordetella parapertussis Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bordetella parapertussis (single agent)
Study: 31709460
Drug: Dietary cobalt
Normalized name: Cobalt
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cobalt supplementation (up to 2 mg/kg)
Study: 31709460
Drug: Dietary cobalt
Normalized name: Cobalt
DrugBank: Cobalt (DB14574)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary cobalt supplementation (3 mg/kg)
Study: 31709460
Drug: 2 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg/kg Co dietary supplementation
Study: 31455473
Drug: Rivaroxaban (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban (15 mg twice daily for 21 days followed by 20 mg once daily)
Study: 31455473
Drug: Warfarin (heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin (heparin for 3 to 5 days followed by warfarin for 3 to 6 months)
Study: 23589565
Drug: Xanthine oxidoreductase
Normalized name: xanthine
DrugBank: Xanthine (DB02134)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Xanthine oxidoreductase (XOR) inhibitor, allopurinol
Study: 12643888
Drug: Bisoprolol low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol low dose (1.25, 2.5 or 3.75mg/day)
Study: 12643888
Drug: Bisoprolol moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol moderate dose (5 or 7.5mg/day)
Study: 12643888
Drug: Bisoprolol high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol high dose (10mg/day)
Study: 2439786
Drug: Bisoprolol (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisoprolol (all doses)
Study: 12643888
Drug: Placebo low
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo low dose
Study: 12643888
Drug: Placebo moderate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo moderate dose
Study: 12643888
Drug: Placebo high
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo high dose
Study: 10777470
Drug: Paclitaxel in
Normalized name: paclitaxel Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel in combination with cisplatin or carboplatin
Study: 1416572
Drug: Subcutaneous octreotide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous octreotide, 100 micrograms every 8 hours for 4 weeks
Study: 1416572
Drug: 300 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 micrograms of octreotide daily for 6 months
Study: 1416572
Drug: 750 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 micrograms of octreotide daily for 6 months
Study: 4014015
Drug: Caffeine (3.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (3.3 mg/kg body weight, equivalent to 2 to 3 cups of coffee)
Study: 26027224
Drug: Usual intensive
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual intensive therapy (IT)
Study: 26027224
Drug: Differentiated therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Differentiated therapy for improvement of renal function
Study: 1978680
Drug: Transdermal nitrate
Normalized name: Nitrate
DrugBank: Nitrate (DB14049)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal nitrate
Study: 10668944
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose oral trimethoprim-sulfamethoxazole
Study: 1898998
Drug: Intravenous flecainide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous flecainide (2 mg/kg, maximum dose 150 mg) with digoxin (500 micrograms)
Study: 7202238
Drug: Dexedrine 2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexedrine 2.5 mg twice daily
Study: 7202238
Drug: Dexedrine 5
Normalized name: Dexedrine 5mg Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexedrine 5 or 10 mg twice daily
Study: 17079762
Drug: Nonsurgical periodontal
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonsurgical periodontal treatment
Study: 27030648
Drug: Blood purification
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood purification group (BP) received continuous venous‐venous hemodiafiltration in addition to conventional treatment.
Study: 22236918
Drug: 3-monthly home
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 3-monthly home visits for questionnaire-based TB screening plus record surveillance of TB registers, hospital admission and X-ray lists at health facilities for TB suspects and cases (Group 1)
Study: 19415341
Drug: 750 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 750 mg/day American ginseng
Study: 19415341
Drug: 1,000 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,000 mg/day American ginseng
Study: 27482750
Drug: 1.25 g
Normalized name: AndroGel 1.25 g Packets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 g testosterone gel (Low T/E)
Study: 27482750
Drug: 5 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 g testosterone gel with letrozole (Normal T/Low E)
Study: 23235130
Drug: Daily chewing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily chewing gum containing xylitol (A)
Study: 12467070
Drug: Liposomal tretinoin
Normalized name: Tretinoin
DrugBank: Tretinoin (DB00755)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Liposomal tretinoin administered once weekly
Study: 10840537
Drug: aprotinin (high-dose-scheme)
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aprotinin (high-dose-scheme)
Study: 10840537
Drug: tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: tranexamic acid (2 g/h)
Study: 10840537
Drug: no antifibrinolytic
Approvals — FDA: no, EMA: no, PMDA: no
Description: no antifibrinolytic therapy (control group)
Study: 6662766
Drug: 75 g
Normalized name: Zosyn 3.375 GM Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 g fructose (F)
Study: 29394188
Drug: Twice weekly
Normalized name: Alora 0.1 MG/Day Twice Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice weekly low‐to‐moderate intensity resistance training
Study: 26206077
Drug: Single administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single administration of fosaprepitant meglumine
Study: 24990067
Drug: Saline infiltration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline infiltration (30 cc)
Study: 20560029
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection of CD133(+) bone marrow stem cells
Study: 17654129
Drug: Salmeterol/fluticasone propionate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmeterol/fluticasone propionate (Seretide) 50/250 microg twice daily (SFC)
Study: 17654129
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate (Flixotide) 250 microg twice daily (FP)
Study: 15857224
Drug: Single-wave bolus
Normalized name: Peumus boldus leaf extract
DrugBank: Boldo leaf extract (DB15815)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-wave bolus (100% of insulin given immediately)
Study: 15857224
Drug: 4-h dual-wave
Normalized name: miconazole
DrugBank: Miconazole (DB01110)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4-h dual-wave bolus (50% of insulin given immediately and 50% given over a 4-h period)
Study: 15857224
Drug: 8-h dual-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8-h dual-wave bolus (50% of insulin given immediately and 50% given over a 8-h period)
Study: 12145009
Drug: High-isoflavone diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-isoflavone diet (56 mg isoflavones/d)
Study: 12145009
Drug: Low-isoflavone diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-isoflavone diet (2 mg isoflavones/d)
Study: 31692016
Drug: Dexamethasone (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (10 mg, 4 times daily for 4 days)
Study: 20593742
Drug: Oral galantamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral galantamine
Study: 18287179
Drug: Pravastatin +
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin + vitamin E + homocysteine-lowering B-vitamin therapy
Study: 17194264
Drug: Active TMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TMS treatment
Study: 17194264
Drug: Active TMS
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active TMS treatment with stimulation intensity below 90% of motor threshold
Study: 11069333
Drug: Nasal first/oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasal first/oral second group
Study: 11069333
Drug: Oral first/nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral first/nasal second group
Study: 9118715
Drug: Inhaled and
Normalized name: Umeclidinium and Vilanterol Inhalation Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled and systemic corticosteroids
Study: 7917772
Drug: Single oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single oral doses of lazabemide (100‐300 mg)
Study: 7917772
Drug: Multiple oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple oral doses of lazabemide (100‐350 mg 12 hourly for 7 days)
Study: 7917772
Drug: Single and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single and multiple dosing of lazabemide
Study: 3288016
Drug: Pentoxifylline (slow-release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline (slow-release formulation) 3 x 400 mg/day for 8 weeks
Study: 31379380
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT), 30 weekly sessions
Study: 29872288
Drug: GB 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB 12.5 μg BID
Study: 29872288
Drug: GB 25
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB 25 μg BID
Study: 29872288
Drug: GB 50
Normalized name: GB-13
DrugBank: GB-13 (DB18387)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GB 50 μg BID
Study: 25045258
Drug: Formoterol 12
Normalized name: formoterol 12 mcg inhalation capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Formoterol 12 μg
Study: 28665378
Drug: General magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General magnetic therapy in addition to initial therapy (medication, therapeutic physical exercises, aquatic therapy)
Study: 28665378
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (initial therapy only)
Study: 28665378
Drug: General magnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: General magnetic therapy
Study: 9847435
Drug: Levalbuterol 1.25
Normalized name: levalbuterol 1.25 mg/3 mL inhalation solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levalbuterol 1.25 mg
Study: 15709454
Drug: Active treatment
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active treatment groups (Levalbuterol and Racemic Albuterol)
Study: 11470011
Drug: Calcium antagonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium antagonist therapy
Study: 11470011
Drug: Diuretic and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretic and beta-blocker therapy
Study: 8635924
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding with a nasogastric tube
Study: 8635924
Drug: Oral feeding
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral feeding without a nasogastric tube
Study: 1617923
Drug: Doxycycline (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (200 mg once daily)
Study: 24760259
Drug: High-dose vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose vitamin D supplementation (5,000 IU daily)
Study: 24047015
Drug: PGE2 vaginal
Normalized name: dinoprostone
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: PGE2 vaginal gel
Study: 11239859
Drug: Topical povidone-iodine
Normalized name: Povidone-Iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topical povidone-iodine (5%) solution applied 10 and 5 minutes before surgery and vancomycin (20 microg/ml) in the irrigating fluid
Study: 11239859
Drug: Topical placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical placebo solution and irrigating fluid only without antibiotics
Study: 9651405
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of elemental zinc daily for 6 months
Study: 2198296
Drug: Zolpidem, an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zolpidem, an imidazopyridine hypnotic compound
Study: 23642977
Drug: Psycho-education along
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psycho-education along with pharmacotherapy treatment
Study: 21285531
Drug: MF59®-adjuvanted formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: MF59®-adjuvanted formulation containing 7.5 μg antigen
Study: 21285531
Drug: Non-adjuvanted formulations
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-adjuvanted formulations containing 15 or 30 μg antigen
Study: 14760339
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of red wine
Study: 14760339
Drug: 250 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mL of dealcoholized red wine
Study: 11740417
Drug: Unfractioned heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unfractioned heparin (UFH) - 5000 units s.c. x 3 daily
Study: 8116325
Drug: Propacetamol 2
Normalized name: 1,2,3-PROPANETRIOL, 2-(4-AMINOBENZOATE)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propacetamol 2 g every 6 hours for 24 hours
Study: 8116325
Drug: Piritramide administration
Normalized name: piritramide
DrugBank: Piritramide (DB12492)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piritramide administration in both groups
Study: 3311480
Drug: Cortisone treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisone treatment (50 mg orally twice daily for 4 days)
Study: 3311480
Drug: Control (absence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (absence of any medication)
Study: 26537948
Drug: Septoplasty (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Septoplasty (with or without concurrent turbinate surgery)
Study: 10482088
Drug: Brimonidine 0.2%
Normalized name: BRIMONIDINE 0.2%/TIMOLOL 0.5% OPH SOLN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brimonidine 0.2% topically twice daily for 29 days
Study: 8735778
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of vitamin C for 14 days
Study: 7038076
Drug: Administration of
Normalized name: IV solutions used in parenteral administration of fluids, electrolytes and nutrients
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administration of fresh-frozen plasma and platelets
Study: 7038076
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no therapy directed specifically at the coagulopathy)
Study: 24756025
Drug: BCI-Manus therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: BCI-Manus therapy
Study: 17624196
Drug: Etoricoxib (90
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib (90 mg, tablet)
Study: 7645522
Drug: Diltiazem plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diltiazem plus trimetazidine (diltiazem 60 mg three times daily and trimetazidine 20 mg three times daily)
Study: 2142741
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy (tissue plasminogen activator)
Study: 2191485
Drug: Intravenous thrombolytic
Normalized name: thrombocytin
DrugBank: Serotonin (DB08839)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous thrombolytic therapy (streptokinase)
Study: 2142741
Drug: Combined trials
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined trials of intravenous thrombolysis
Study: 23339726
Drug: Combination aliskiren/valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination aliskiren/valsartan 150/160 mg
Study: 16804292
Drug: Ketoconazole 100
Normalized name: ketoconazole 100 % MISCELL CRYSTALS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketoconazole 100 mg/day
Study: 27263310
Drug: 15 mL
Normalized name: ethanol 0.15 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mL normal saline
Study: 27263310
Drug: 0 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mL normal saline (control group)
Study: 18088197
Drug: Galantamine (16-24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galantamine (16-24 mg/day)
Study: 15519702
Drug: DTPa/Hib (PRP-T)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa/Hib (PRP-T) booster dose
Study: 15519702
Drug: Unconjugated PRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Unconjugated PRP (PRP) challenge dose plus separate DTPa vaccine
Study: 11356400
Drug: Lipid-lowering therapy
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapy or other pharmacologic therapy started before discharge
Study: 11356400
Drug: Systematic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systematic treatment plans for management of risk factors after hospitalization
Study: 19265635
Drug: Combination therapies
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapies with second-generation antipsychotics (e.g., olanzapine, risperidone, quetiapine, aripiprazole) combined with lithium or divalproex
Study: 7617495
Drug: APF gel
Normalized name: APF Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: APF gel
Study: 3883938
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy alone (n = 18)
Study: 3883938
Drug: Cognitive therapy
Normalized name: cognitive therapy software
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive therapy plus amitriptyline hydrochloride (n = 15)
Study: 3883938
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment at one-year follow-up
Study: 29273308
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy (NACT) with carboplatin and paclitaxel (CT) followed by interval cytoreductive surgery and then 3 additional cycles of CT
Study: 27447802
Drug: 40 mg
Normalized name: rutin 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 40 mg submucosal injection of prednisolone
Study: 17916949
Drug: Adjuvant sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant sodium selenite 0.2 mg kg‐1 day‐1 for 30 days in addition to standard chemotherapy
Study: 15613422
Drug: Flaxseed (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flaxseed (40 g/d)
Study: 7770605
Drug: Vitamin supplementation
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin supplementation (ten times the recommended daily dose of nine vitamins)
Study: 17355546
Drug: Ergotamine 2
Normalized name: ergotamine 2 mg sublingual tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergotamine 2 mg plus caffeine 200 mg
Study: 6962709
Drug: Slow release
Normalized name: Slow Release Iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow release oxprenolol (160-320 mg/day)
Study: 6962709
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (oxprenolol and chlorthalidone, and hydrallazine)
Study: 30477309
Drug: EDS‐FLU 93
Approvals — FDA: no, EMA: no, PMDA: no
Description: EDS‐FLU 93 µg, 186 µg, or 372 µg
Study: 10433447
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg allopurinol orally on admission and a further 300 mg for another 5 days
Study: 1703602
Drug: Cromakalim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim (1 mg) single dose
Study: 1703602
Drug: Cromakalim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim (1 mg) added to atenolol
Study: 1703602
Drug: Cromakalim (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromakalim (1 mg)
Study: 26261902
Drug: GAD antibodies
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GAD antibodies
Study: 26261902
Drug: IA2 antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA2 antibodies
Study: 31045465
Drug: Curcuminoids 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcuminoids 4 g/day
Study: 22271159
Drug: Valsartan (320
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan (320 mg)
Study: 25853236
Drug: Nebivolol-Valsartan combination
Normalized name: nebivolol / valsartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebivolol-Valsartan combination (20/320 mg)
Study: 16310713
Drug: 0.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg/kg oral morphine sulphate
Study: 23419343
Drug: 0.05 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 mg/kg oral midazolam (active placebo)
Study: 15293527
Drug: Manidipine (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manidipine (10-20 mg/day)